Niagen Bioscience, Inc. (NAGE)
NASDAQ: NAGE · Real-Time Price · USD
10.12
-0.14 (-1.36%)
At close: Aug 13, 2025, 4:00 PM
10.23
+0.11 (1.09%)
After-hours: Aug 13, 2025, 7:14 PM EDT
Niagen Bioscience Stock Forecast
Stock Price Forecast
According to 3 professional analysts, the 12-month price target for Niagen Bioscience stock ranges from a low of $12 to a high of $23. The average analyst price target of $17 forecasts a 67.98% increase in the stock price over the next year.
Price Target: $17.00 (+67.98%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Niagen Bioscience stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 2 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $11 → $12 | Strong Buy | Maintains | $11 → $12 | +18.58% | Aug 11, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $13 → $16 | Strong Buy | Maintains | $13 → $16 | +58.10% | Jun 10, 2025 |
| Roth Capital | Roth Capital | Strong Buy Maintains $10 → $23 | Strong Buy | Maintains | $10 → $23 | +127.27% | Jun 6, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Initiates $13 | Strong Buy | Initiates | $13 | +28.46% | May 27, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +8.70% | Apr 8, 2025 |
Financial Forecast
Revenue This Year
125.93M
from 99.60M
Increased by 26.44%
Revenue Next Year
151.19M
from 125.93M
Increased by 20.06%
EPS This Year
0.13
from 0.11
Increased by 20.55%
EPS Next Year
0.24
from 0.13
Increased by 84.62%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 130.7M | 157.5M | 189.7M |
| Avg | 125.9M | 151.2M | 180.9M |
| Low | 119.3M | 142.9M | 170.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 31.3% | 25.1% | 25.5% |
| Avg | 26.4% | 20.1% | 19.7% |
| Low | 19.8% | 13.5% | 12.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 0.24 | 0.37 | 0.41 |
| Avg | 0.13 | 0.24 | 0.37 |
| Low | 0.08 | 0.17 | 0.33 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 119.5% | 177.1% | 67.3% |
| Avg | 20.5% | 84.6% | 52.1% |
| Low | -28.7% | 25.6% | 36.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.